Stablecoin Development Corporation · AMEX:SDEV
Stablecoin Development — NovaBay Pharmaceuticals — Corporate Update (April 2024)
22 slides from Stablecoin Development's corporate update, Apr 22, 2024
Slide 1: Corporate Update April 2024
N@®vaBay PHARMA Corporate Update April 2024 NYSE American: NBY
Slide 2: Forward-Looking Statements
N™@vaBay Forward-Looking Statements ements, within the meaning of in some cases, be ward-looking which statements can, ject” “believe,” “may,” “ol _ ‘expect “target! al’ and other similar expressions. These for king statements reflect Novabay’s current expectation and assumptions, such as expected m
Slide 3: Corporate Overview
N@vaBay Corporate Overview Established, High-Quality High-Margin Brands Avenova + The #1 doctor-recommended antimicrobial tid & lash spray In the US. dry eye market Avenova-branded Portfolio + Be |-class Avenova products for each step of the standard dry-eye treatment regimen PhaseOne and NeutroPhas
Slide 4: Investment Highlights
N™@vaBay Investment Highlights Predictable, Recurring Revenue Multipronged Growth Strategy Expense Management High-quality products & customer Focus on driving growth through DTC sales & marketing expertise loyalty provide solid foundation of multiple sales channels and contributed to 17% YOY decrea
Slide 5: Strategic Execution to Drive Sales in Large Eyecare Market
N@vaBay Strategic Execution to Drive Sales in Large Eyecare Market 4 EXPAND PRODUCT PORTFOLIO Extend produc ing to become one-stop fora 2. INCREASE DISTRIBUTION pror 3 BROADEN SALES CHANNEL
Slide 6: Executing on Business Strategy
N®vaBay Executing on Business Strategy lograft, a raft for Use ng the Repair of Ocular Surfaces motion for Rx Ophthalmic Pro - to vannel areness
Slide 7: Eyecare
eyecare
Slide 8: Avenova
AVENOVA’ purely ye. SCIENCE FOR SORE EYES. + No.1 Doctor-Recommended Antimicrobial Lid & Lash Spray + Pioneering use of hypochlorous acid (HOCI) - a substance naturally produced by the body ~ for antimicrobial lid & lash spray + kills a broad spectrum of bacteria and helps relieve chronic eye condit
Slide 9: Avenova Efficacy Advantages
N@vaBay Avenova Efficacy Advantages and moet powerful + Bottled in amber glass to ensure the safest, pur HOGI lid & lash spray on the market The Avenova Difference. Prt longet-sting formation of HOCt No stinging oration Non-toxe and nan-sensitzng ‘compat sae ferro. lng-trm vse oe sete tor etre!
Slide 10: Avenova Sales Channels
N@®vaBay Avenova Sales Channels Rx - Retail Pharmacy Physician Dispensed orc + Physicians prescribe Avenova + Physicians purchase Avenova + Physicians refer patients to See ey Rx 20mL, at a discounted ‘Avenova.com, Amazon, EF their choice (cvs ipa cea legs Walmart & CVS Walgreens, Walmart, Rte ld, p
Slide 11: Avenova Opportunities for Growth
N@vaBa) Avenova Opportunities vaBay for Growth — AVENOVA (D> t+ Reta pharmacy ( + Partnership wth imorimisRx. the nations largest ophthalmic Novawir | Physician Dispensed be] New products and ncemotional programe bulldon recent sales channel momentuen + Promotedthrougt mail sequencing campaigns a +
Slide 12: Capitalizing on Physician Dispensed Channel
N®vaBay Capitalizing on Physician Dispensed Channel Established relationships with thousands of eyecare specialists ‘opens new revenue opportunities New affiliate programs provide network with access to special promotions aimed at increasing awareness of full suite ofF Avenova products + Marketing o
Slide 13: Introducing Avenova Allograft
Introducing AVENOVA ALLOGRAFT FEATHER LIGHT, BUT POWERFUL New Differentiated, High-Quality Product Addressing Large Market Opportunity @ Licensed & rebranded proprietary Rx product from BioStem Technologies @ Recent commercial launch through Physician Dispensed channel / @ Global ophthalmology amnio
Slide 14: Co-Promotion Partnership for Rx Ophthalmic Products
N@vaBay eyenovia Co-Promotion Partnership for Rx Ophthalmic Products Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company commercializing Mydcombi™ —(tropicamide+phenylephrine ophthalmic spray for mydriasis) and d * NovaBay to market newly FDA-approved steroid in. connecti
Slide 15: Continued Growth in DTC Channel
Continued Growth in DTC Channel Vast majority of unit sales are currently through OTC channel Broad product accessibility through major online retailers and in-store stocking at CVS Online “Subscribe & Save” feature on Avenova.com and Amazon.com, for repeat orders and revenue stabilization Core expe
Slide 16: Highly Loyal Customer Base
Highly Loyal Customer Base 2023 year-over-year increases from leading OTC channels, Amazon.com and Avenova.com, provide evidence of high customer satisfaction and loyalty High-quality products and high customer satisfaction 64% year-over-year increase in online provides predictable revenue @ subscri
Slide 17: Complete Avenova-Branded Dry Eye Product Portfolio
N@vaBay Complete Avenova-Branded Dry Eye Product Portfolio One product for each step in the standard dry eye treatment regimen
Slide 18: Wound Care
wound care
Slide 19: Cutting-Edge Wound Care Technology
N™@®vaBay The safe and effective HOCI solution for managing viruses, bacteria and fungi Cutting-Edge Wound Care Technology Leverages NovaBay proprietary HOCL technology Rx product for routine and tough cases Distributed through partners PhaseOne Health (US.) Pioneer Pharma (China)
Slide 20: Summary
N@vaBay summary Page 20
Slide 21: Financial Highlights
N@vaBay Financial Highlights Eye and wound care product sales for 2023 reach 1 $112 million, up 9% over the prior year Sales & marketing spend for 2023 decreased by 2 17% from prior year Cash and cash equivalents of $3.1 million as of December 31, 2023
Slide 22: Investment Highlights
N™@vaBay Investment Highlights Predictable, Recurring Revenue Multipronged Growth Strategy Expense Management High-quality products & customer Focus on driving growth through DTC sales & marketing expertise loyalty provide solid foundation of multiple sales channels and contributed to 17% YOY decrea
NovaBay Pharmaceuticals — Corporate Update (April 2024) on 6ix